Vivesto AB

Vivesto AB, established in 1988 and headquartered in Solna, Sweden, specializes in the development, production, commercialization, and sale of pharmaceutical products within human and veterinary oncology, primarily operating in its home country. Its leading human oncology product is Apealea (paclitaxel micellar), designed for the treatment of ovarian cancer. The company's pipeline for human health also includes Docetaxel micellar, a patented formulation combining the cytotoxin docetaxel with XR-17, which is currently in Phase 1b clinical trials for prostate cancer, as well as Cantrixil for addressing ovarian cancer. For animal health, Vivesto provides Paccal Vet, leveraging its XR-17 encapsulation technology to deliver paclitaxel for canine mastocytoma, and Doxophos Vet, a proprietary doxorubicin formulation used to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) until its name change to Vivesto AB in March 2022.